An American Action Forum (AAF) data analysis that connects increases in consumer drug spending with the introduction of 340B drug discount and Medicaid drug rebate program policies “is spurious at best,” says an expert on prescription drug costs whose research has found that 340B inflation penalties restrain drug price growth.
AAF, a think tank closely-aligned with the congressional Republican leadership and the pharmaceutical industry, published the analysis online on May 13. It “examines how retail spending per capita on prescription drugs has correlated with the introduction and expansion of the MDRP and 340B program, with specific emphasis on the 340B program,” AAF Health Care Policy Analyst Jackson Hammond wrote.
An American Action Forum (AAF) data analysis that connects increases in consumer drug spending with the introduction of 340B drug discount and Medicaid drug rebate program policies “is spurious at best,” says an expert on prescription drug costs whose research has found that 340B inflation penalties restrain drug price growth.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.